RGBOQ — ReGen Biologics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -855.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2004 | 2005 | 2006 | 2007 | 2008 | 2009E | 2010E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.5 | 0.57 | 0.59 | 0.99 | 1.37 | n/a | n/a | 36.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ReGen Biologics, Inc. (ReGen) is a development stage orthopedic products company that develops, manufactures and markets tissue growth and repair products for United States and global markets. The Company's collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. Some of these applications are marketable while others are in various stages of development. ReGen’s first approved product using its collagen matrix technology is the Menaflex collagen meniscus implant device (also known as the CMI), which is marketed for sale in the European Union (EU), Switzerland, Turkey, and the Republic of South Africa, through the Company’s subsidiary, ReGen Biologics AG.
Directors
- Gerald Bisbee CHM (78)
- Dennis O'Dowd CFO
- Jeffrey Chandler SVP (53)
- John Dichiara SVP (59)
- James Flounlacker SVP (52)
- William Rodkey VPR (66)
- Alan Baldwin DRC (73)
- J Steadman DRC (75)
- William Timken DRC (78)
- Last Annual
- December 31st, 2008
- Last Interim
- June 30th, 2009
- Incorporated
- September 1st, 1987
- Public Since
- June 28th, 1996
- No. of Shareholders
- 234
- No. of Employees
- 16
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 9,778,940
- Address
- 411 Hackensack Ave Fl 10, HACKENSACK, 07601-6326
- Web
- http://www.ivysportsmed.com/
- Phone
- +1 2016515140
- Auditors
- Ernst & Young LLP
Similar to RGBOQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
As of Today at 18:17 UTC, shares in ReGen Biologics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in ReGen Biologics last closed at $0.00 and the price had moved by -99.97% over the past 365 days. In terms of relative price strength the ReGen Biologics share price has underperformed the S&P500 Index by -99.97% over the past year.
There is no consensus recommendation for this security.
ReGen Biologics does not currently pay a dividend.
ReGen Biologics does not currently pay a dividend.
ReGen Biologics does not currently pay a dividend.
To buy shares in ReGen Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in ReGen Biologics had a market capitalisation of .
Here are the trading details for ReGen Biologics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RGBOQ
Based on an overall assessment of its quality, value and momentum ReGen Biologics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ReGen Biologics. Over the past six months, its share price has underperformed the S&P500 Index by -100%.
As of the last closing price of $0.00, shares in ReGen Biologics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ReGen Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ReGen Biologics' management team is headed by:
- Gerald Bisbee - CHM
- Dennis O'Dowd - CFO
- Jeffrey Chandler - SVP
- John Dichiara - SVP
- James Flounlacker - SVP
- William Rodkey - VPR
- Alan Baldwin - DRC
- J Steadman - DRC
- William Timken - DRC